ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533 an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944 an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114 a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco California.